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Abstract
Background and Objectives FE 999049 is a novel re-
combinant follicle-stimulating hormone (rFSH) preparation
expressed by a human cell line (PER.C6), in contrast to
existing rFSH preparations expressed by Chinese hamster
ovary (CHO) cell lines. Since the individual dose of rFSH
may be altered depending on the response in women un-
dergoing assisted reproductive technologies, knowledge on
the dose-exposure linearity and proportionality is impor-
tant. The purpose of these studies was to investigate the
dose-exposure linearity and proportionality properties of
FE 999049 with a comparison between Caucasian and
Japanese women. This is the first study in Japanese women
regarding pharmacokinetics of rFSH.
Methods Forty-eight Caucasian and 31 Japanese healthy
women of reproductive age were pituitary down-regulated
to suppress endogenous FSH. Following single subcuta-
neous administration of 37.5, 75, 150, 225, or 450 IU
(Steelman–Pohley assay), the serum FSH concentration
was followed over 10 days.
Results The dose-dependent pharmacokinetic parameters
of FE 999049, area under the serum concentration-time
curve (AUC) and maximum serum concentration (Cmax),
showed dose-exposure linearity and proportionality over
150–450 IU in Caucasian women, the dose interval avail-
able for analysis, and 75–450 IU in Japanese women,
which was the dose interval investigated. Comparison be-
tween Caucasian and Japanese women showed no differ-
ences between the populations. The dose-independent
parameters were similar over all doses in both populations.
FE 999049 was safe and well tolerated at all doses in both
populations with few, mostly mild, adverse events.
Conclusion The results demonstrate dose-exposure pro-
portionality and a predictable dose-dependent exposure of
FE 999049, with no differences in Caucasian and Japanese
women of reproductive age.
Key Points
Dose-exposure proportionality for both AUC and
Cmax was demonstrated for the novel rFSH
FE 999049 in the dose range 75–450 IU in
Caucasian and Japanese women.
There were no differences in pharmacokinetic
properties and dose proportionality between
Caucasian and Japanese women, this being the first
report on the pharmacokinetics of rFSH in a
Japanese population.
The results provide important information for the
selection of dose when a change in dose is required
during the treatment with rFSH in women
undergoing assisted reproductive technologies.
1 Introduction
Follicle-stimulating hormone (FSH) is a key hormone in
both male and female reproductive functions. It is produced
in the anterior pituitary gland and stimulates growth and
maturation of ovarian follicles in women [1] while it
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promotes spermatogenesis in men [2]. The synthesis and
release of FSH is mainly controlled by the secretion of
gonadotropin-releasing hormone (GnRH) from the hy-
pothalamus. In addition to the ovaries, animal data indicate
that FSH is distributed to the kidney and liver [3, 4], and
mainly eliminated by the kidney [4, 5].
FSH is a glycoprotein composed of two non-covalently
bound polypeptide chains, denoted a and b. Pituitary FSH,
pituitary luteinizing hormone (LH), pituitary thyroid-s-
timulating hormone (TSH), and placental chorionic go-
nadotropin (hCG) all share the same a-subunit. In contrast,
the structurally different b-subunit is unique to each of the
hormones. Both subunits of FSH are N-glycosylated at two
positions, the carbohydrates accounting for nearly one-
third of the total mass, which give rise to numerous iso-
forms of the molecule with substantial variations in size
and structure of the carbohydrate chains as well as the level
of sialylation [6, 7]. The composition of the carbohydrate
moieties affects the activity of FSH in vivo by influencing
the clearance, the binding properties to the FSH receptor,
and the ability to activate the receptors. Generally, more
acidic isoforms have a lower clearance [8–10], while a
higher number of sialic acid residues has commonly been
reported to be associated with increased biological activity
in vitro and in vivo [8, 11–14].
Since the introduction of recombinant FSH (rFSH) in
the mid-1990s it has been widely used in the treatment of
infertility. Currently, the available rFSH products used for
controlled ovarian stimulation (COS) in women undergo-
ing in vitro fertilization (IVF) or intracytoplasmic sperm
injection (ICSI) cycles, i.e., follitropin a and follitropin b,
are expressed in Chinese hamster ovary (CHO) cell lines
[15]. Recently, a novel rFSH (FE 999049) derived from a
cell line of human fetal retinal origin (PER.C6) entered
clinical development. The amino acid sequences of the a-
and b-subunits of FE 999049 are identical to the sequence
of natural human FSH and existing CHO-derived rFSH
products in clinical use. However, the sialic acid content of
FE 999049 is different and more complex, with both a2,3
and a2,6 sialylation compared with the CHO-derived FSH
products, which only contain a2,3 sialylation, and thus
more resembling the natural human FSH than products
from CHO cell lines [16].
FE 999049 has previously been reported to have a lower
clearance with higher exposure and pharmacodynamic re-
sponse compared to CHO-derived rFSH [17] when equally
dosed by bioactivity as assessed in rats (Steelman–Pohley
assay [18]). Dose proportionality which is an important
property in order to predict exposure and the consequent
ovarian response when increasing or decreasing the dose,
was not investigated in this study. In addition, since the
need for assisted reproductive technologies is growing
worldwide, there needs to be an understanding of the
conformity in different populations. This report presents
results from the first-in-human study in Caucasian women,
and a dedicated rFSH study in Japanese women, investi-
gating the pharmacokinetic dose-exposure proportionality
properties of FE 999049, a novel rFSH derived from a




The study protocols and informed consent documents were
reviewed and approved by Independent Investigational
Review Board Inc., Plantation, Florida, USA, and Compass
IRB, Mesa, Arizona, USA, respectively. The studies were
conducted in accordance with Declaration of Helsinki and
the principles of Good Clinical Practice at Clinical Phar-
macology of Miami, USA (Caucasian study), and West
Coast Clinical Trials, LLC, Cypress, California, USA (Ja-
panese study). Prior to screening, written informed consent
was obtained from all subjects.
The investigations were designed as double-blind,
placebo-controlled, within-group randomized, parallel-
group studies. There were five ascending dose panels of
FE 999049, 37.5, 75, 150, 225, and 450 IU, in Caucasian
women (‘Caucasian’ study) and four ascending dose pan-
els, 75, 150, 225, 450 IU, in Japanese women (‘Japanese’
study) with eight healthy women in each dose panel (six
active treatment, two placebo). A direct comparison be-
tween Japanese and Caucasian women was made by adding
eight Caucasian women (six active, two placebo) at the
highest dose, 450 IU, to the ‘Japanese’ study.
Subjects found to be eligible started a high-dose com-
bined oral contraceptive (OGESTREL 0.5/50, Watson
Pharma Inc., Morristown, NJ, USA) run-in period before
administration of rFSH to suppress endogenous FSH, and
daily administrations of combined oral contraceptive then
continued throughout the study. Three days and one day
before administration of rFSH, blood samples were col-
lected for analysis and eligibility check of the FSH and
estradiol concentrations. If FSH was [5 IU/L or estradiol
was[50 pg/ml in any of the measurements the subject was
excluded from the study.
On the day of rFSH administration, each subject was
randomized to receive a bolus subcutaneous injection of
either FE 999049 or placebo according to a computer-
generated randomization list with a block size of 8, pro-
vided by an independent statistician. Blood samples for
pharmacokinetic analysis were collected pre-dose, and 4, 8,
12, 16, 20, 24, 28, 32, 36, 40, 44, 48 h, and 3, 4, 5, 6, 7, 8,
and 9 days after administration.
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2.2 Subjects
Healthy Caucasian and Japanese women, 21–35 years of
age, were enrolled. The main inclusion criteria were body
mass index (BMI) between 18 and 29 kg/m2, menstrual
cycle of 24–35 days, and with no clinically significant
findings in gynaecological examinations, vital signs, ECG,
or laboratory parameters.
2.3 Sources and Analysis of FE 999049
All references to FSH activity (IU) are based on the method
by Steelman and Pohley [18]. FE 999049 was produced in
a cell line of human fetal retinal origin (PER.C6) and
provided as a sterile phosphate-buffered solution of
pH 6–7. The concentration of the active ingredient was
600 IU/mL FSH activity, to be used undiluted.
Analyses of serum FSH concentrations were performed
by the Department of Bioanalysis at Ferring Pharmaceuti-
cals A/S by means of a validated immunoassay based on
electrochemiluminiscence (ECL). Briefly, a 96-well mi-
croplate was coated with a mouse anti-human FSH anti-
body (AbD Serotec, Oxford, UK) over night, after which
samples were transferred by the aid of a Tecan Genesis
Freedom sample handling robot. After adding the MSD-
SULFO-TAG labeled mouse anti-human FSH antibody and
incubating for 1 h, the color was developed and read with
an MSD Sector Imager 2400. The lower limit of quantifi-
cation for FE 999049 was 1.32 mIU/mL as determined
from QC samples. The bias at all levels was within ±9 %,
and the bias for back-calculated calibration samples within
8 %.
2.4 Statistical Analyses
The pharmacokinetic parameters of FE 999049 were
calculated for baseline corrected data, assuming a con-
stant background FSH concentration, by non-compart-
mental analysis (NCA) using the software
WinNonlinPro (Pharsight Corporation, Cary, NC, USA).
The baseline value was the mean of the values obtained
prior to the first administration of rFSH. Serum con-
centration values below the lower limit of quantitation
and missing values (e.g., no blood sample collected or no
value obtained at analysis) were excluded from the NCA.
Actual time-points for blood sampling were used in the
calculations of the individual parameters, while nominal
time-points are denoted for summary statistics. Pharma-
cokinetic parameters were estimated based on measure-
ments from Day 1 to the last day of pharmacokinetic
assessment, i.e., Day 10.
Descriptive statistics were calculated for serum con-
centrations and pharmacokinetic parameters, and all
pharmacokinetic parameters were compared across treat-
ment groups using an ANOVA model for the log-trans-
formed values. The ratios of the pharmacokinetic
parameters were estimated with 90 % confidence limits.
All statistical analyses were performed using SAS software




Seventy-nine healthy women, 48 Caucasian and 31 Ja-
panese, aged between 21 and 35 years were randomized
and dosed. The bodyweight ranged from 47 to 90 and 43 to
74 kg for the Caucasians and Japanese women, respec-
tively, and the corresponding BMI ranged from 18.7 to
28.9 and 18.2 to 28.1 kg/m2, respectively. The treatment
groups within each study were comparable with respect to
all demographic parameters (Table 1) as well as con-
comitant medication and medical history. All subjects
completed the study.
3.2 Pharmacokinetic Evaluation
Following a single subcutaneous administration of
FE 999049 the serum FSH concentration increased to reach
a maximum approximately 20 h after injection in all dose
groups in both Caucasian and Japanese subjects. The FSH
levels subsequently declined slowly with an approximate
terminal half-life of 40 h, similar in all dose groups in both
populations (Fig. 1). All placebo subjects except one had at
all time-points serum FSH levels below limit of
quantitation.
The dose-dependent pharmacokinetic parameters of
FE 999049, area under the serum concentration-time curve
(AUC) and maximum serum concentration (Cmax), in-
creased with increasing doses in both Caucasian (Table 2)
and Japanese (Table 3) women. Analysis of the dose pro-
portionality indicated a linear relationship (all correlation
coefficients[0.985) for both AUC and Cmax, (Fig. 2) with
slopes being 1.0, or close to, thus showing dose propor-
tionality (Table 4). Comparison of the results in the Ja-
panese and Caucasian women between trials did not show
any significant differences, and none of the dose-dependent
parameters showed any significant difference between the
two populations. In addition, the head-to-head comparison
between Japanese and Caucasian subjects administered 450
IU in the same study showed very similar results on both
AUC and Cmax for the two groups (Table 2).
The dose-independent pharmacokinetic parameters re-
mained similar over the dose range, both within and
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between the two populations without any significant dif-
ferences between doses or populations (Tables 2, 3).
3.3 Safety
All doses were safe and well tolerated in the Caucasian and
Japanese subjects. The safety profile of FE 999049 in this
trial was acceptable with a few adverse events occurring
sporadically in all treatment groups, including the placebo
groups, and almost all being of mild intensity. Ten and
seven of the adverse events reported by nine (25 %) Cau-
casian and four (17 %) Japanese subjects on active treat-
ment were regarded as related to treatment, and also six
(50 %) and two (25 %) Caucasian and Japanese placebo
subjects reported eight and three adverse events that were
regarded as related to treatment. With few exceptions the
adverse events (AEs) occurred as single events in various
treatment groups, including the placebo groups, with no
apparent relation to dose or subject origin. The most fre-
quently reported related AEs in all of the 79 subjects were
headache (nine events), injections site reactions at 30 min
or later (five events), and abdominal pain (four events),
occurring in both active treatment as well as placebo
groups. All related AEs were mild except for one moderate
headache, and no subject discontinued due to an AE. The
injection site reactions were generally mild and of short
duration, occurring also in the placebo groups.
There were no apparent trends or dose-related changes
in any of the laboratory parameters clinical chemistry, in-
cluding liver and kidney functions, haematology,
haemostasis, vital signs, or ECG parameters, and no dif-
ferences were observed between Caucasian and Japanese
subjects. No laboratory parameter value was regarded as
clinically significant.
Fig. 1 Time courses of serum FSH mean concentrations after single
subcutaneous administrations of FE 999049 to healthy women.
a Caucasian women including the group participating in the
‘Japanese’ study. b Japanese (75–450 IU) and Caucasian (450 IU)
healthy women. Values are mean ± standard error of mean
Table 1 Summary of demographic characteristics according to FE 999049 dose
Characteristic 37.5 IU 75 IU 150 IU 225 IU 450 IU 450 IUa Placebo
Caucasians N = 6 N = 6 N = 6 N = 6 N = 6 N = 6 N = 12b
Age (years) 30.7 (5.2) 30.1 (4.5) 26.8 (3.0) 30.9 (3.7) 28.0 (5.1) 26.2 (3.3) 28.9 (3.1)
Weight (kg) 59.4 (9.2) 70.8 (6.1) 68.4 (14.8) 61.5 (5.3) 61.6 (6.6) 61.9 (7.1) 66.3 (11.0)
BMI (kg/m2) 23.5 (2.5) 26.2 (2.1) 24.3 (4.3) 24.3 (2.2) 23.7 (3.0) 22.5 (2.6) 25.0 (3.5)
Japanese N = 6 N = 6 N = 5 N = 6 N = 8
Age (years) NA 29.0 (4.1) 29.6 (4.3) 26.6 (3.0) 26.8 (4.2) 27.0 (4.7)
Weight (kg) NA 52.5 (6.3) 49.8 (2.9) 60.7 (7.0) 54.9 (7.8) 55.6 (9.0)
BMI (kg/m2) NA 20.1 (1.3) 20.3 (1.5) 23.4 (2.3) 20.8 (2.9) 21.2 (3.0)
Values are means with standard deviation
BMI body mass index, N number of subjects, NA not applicable
a Participating in the ‘Japanese’ study
b Two of whom from the ‘Japanese’ study
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4 Discussion
The wide-spread use of rFSH in assisted reproductive
technologies at doses on-demand, imply a trust that the
administered dose results in the expected serum concen-
tration and ovarian response. The results of the present
dose-exposure proportionality studies demonstrate that
rFSH manufactured from a human cell line (PER.C6),
with proven different glycosylation than CHO-derived
rFSH, show predictable and consistent pharmacokinetic
behaviour after single subcutaneous administrations in
Caucasian and Japanese women within a dose range cov-
ering the clinical use of rFSH. Pharmacokinetic dose pro-
portionality has previously been demonstrated for CHO-
derived rFSH up to the maximal tested dose 225 IU [19],
and in this study dose-exposure proportionality with the
human cell line-derived rFSH was demonstrated even
further, up to 450 IU.
To our knowledge this is the first dedicated investigation
with rFSH in Japanese women. As for Caucasian women,
FE 999049 showed dose-exposure proportionality, and the
comparison with Caucasian women showed no statistical
differences, clearly demonstrating that the pharmacokinetic
characteristics of FE 999049 were similar between these
populations. Further, no statistical differences were ob-
served neither within the Caucasian nor the Japanese dose
groups when comparing dose normalised dose-dependent
pharmacokinetic parameters, and neither were any differ-
ences observed comparing the dose-independent pa-
rameters. The recently demonstrated linear dose-response
relationship in pharmacodynamic effect [20] further sub-
stantiates the predictable behaviour of the rFSH derived
from the human cell-line, and together with the present
data show that similar dosing regimens can be employed in
populations of different origin.
The administration of single doses of FE 999049 to
healthy women demonstrated very similar concentration-
time profiles over the dose range investigated. The serum
concentrations of FE 999049 in the two lowest dose groups
in Caucasians were very low, preventing meaningful
Table 2 Pharmacokinetic parameters of FE 999049 in Caucasian women following a single subcutaneous administration according to
FE 999049 dose
Parameter ‘Caucasian’ study ‘Japanese’ study Studies combined
150 IU (N = 6) 225 IU (N = 6) 450 IU (N = 6) 450 IU (N = 6) 450 IU (N = 12)
AUC (mIUh/mL) 325 (184) 519 (171) 1158 (138) 1258 (215) 1207 (180)
AUCt (mIUh/mL) 254 (162) 447 (153) 1052 (136) 1187 (227) 1120 (191)
Cmax (mIU/mL) 4.4 (1.9) 7.2 (1.7) 14.7 (3.2) 16.1 (1.9) 15.4 (2.6)
tmax (h) 20 (8–24) 20 (16–28) 20 (16–24) 20 (20–20) 20 (16–24)
t (h) 39 (8) 40 (21) 44 (6) 43 (6) 44 (6)
CL/F (L/h) 0.70 (0.56) 0.50 (0.26) 0.39 (0.05) 0.37 (0.06) 0.38 (0.05)
Vz/F (L) 34 (19) 24 (9) 25 (6) 23 (3) 24 (5)
Values are presented as mean (SD) except for tmax values, which are presented as medians with range
N number of subjects, AUC area under the serum concentration-time curve, AUCt AUC from time 0 to time t, Cmax maximum serum con-
centration, tmax time to reach Cmax, t elimination half-life, CL/F apparent clearance, Vz/F apparent terminal volume of distribution
Table 3 Pharmacokinetic parameters of FE 999049 in Japanese women following a single subcutaneous administration according to FE 999049
dose
Parameter Japanese
75 IU (N = 6) 150 IU (N = 6) 225 IU (N = 5) 450 IU (N = 6)
AUC (mIUh/mL) 212 (91) 455 (96) 553 (97) 1252 (282)
AUCt (mIUh/mL) 153 (69) 374 (92) 469 (98) 1155 (308)
Cmax (mIU/mL) 3.2 (0.8) 6.4 (1.2) 7.6 (1.6) 17.3 (5.8)
tmax (h) 18 (8–20) 20 (12–24) 20 (20–32) 20 (20–24)
t (h) 38 (13) 37 (5) 40 (2) 43 (11)
CL/F (L/h) 0.41 (0.17) 0.34 (0.08) 0.48 (0.12) 0.38 (0.09)
Vz/F (L) 23 (16) 18 (3) 28 (8) 25 (13)
Values are presented as mean (SD) except for tmax values, which are presented as medians with range
N number of subjects, AUC area under the serum concentration-time curve, AUCt AUC from time 0 to time t, Cmax maximum serum
concentration, tmax time to reach Cmax, t elimination half-life, CL/F apparent clearance, Vz/F apparent terminal volume of distribution
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pharmacokinetic parameters to be calculated, but the gra-
phical presentation still demonstrated a similar general
concentration time-course as for the higher dose groups.
Dose-exposure proportionality was demonstrated for AUC
and Cmax over the range 150–450 IU in Caucasian women
and 75–450 IU in Japanese women, thus covering the
predominant part of the expected dose range in the clinical
setting. The dose-independent kinetic parameters tmax, t,
apparent clearance (CL/F), and apparent terminal volume
of distribution (Vz/F) were all similar over the dose range
and between study populations, supporting the pre-
dictability of the pharmacokinetics of varying doses of
FE 999049. It is therefore reasonable to assume that dose-
exposure proportionality extends to 75 IU also for the
Caucasian women.
The results for 450 IU of the recombinant human FSH in
this study compared well with the results previously re-
ported with a single subcutaneous dose of 450 IU with
respect to all the pharmacokinetic parameters [17], sub-
stantiating the consistent exposure with FE 999049. Com-
pared with literature reports of single subcutaneous
administrations of rFSH of CHO origin, the exposure
tended to be greater by means of both AUC and Cmax [19,
21, 22], which is in line with the report on direct com-
parison at a single dose level between the two rFSH
preparations [17].
In order to accurately determine the pharmacokinetic
properties of exogenously added rFSH, the suppression of
endogenous FSH production is essential. For the purpose of
minimising the interference by endogenous FSH in the
pharmacokinetic analysis, all women were taking a com-
bined oral contraceptive, which was sufficient to suppress
the endogenous FSH to levels \5 mIU/mL prior to the
administration of FE 999049. The efficacy was demon-
strated by [95 % of the women having endogenous FSH
levels at baseline that were below the lower limit of
quantitation.
The safety profile of FE 999049 was favourable with
only a few AEs occurring sporadically in all treatment
groups, including the placebo groups, and almost all being
of mild intensity with no differences in the safety profile
between Caucasian and Japanese women. Overall, the re-
sults did not cause any concerns regarding tolerability.
In conclusion, a single subcutaneous administration of
the novel rFSH from a human cell line, FE 999049, showed
dose proportionality in the range 37.5–450 IU in healthy
Caucasian and Japanese women of reproductive age.
Moreover, there were no significant differences in the
pharmacokinetic characteristics between the two
populations.
5 Conclusion
In summary, dose-exposure proportionality for both AUC
and Cmax was demonstrated for the novel subcutaneous
Fig. 2 Dose linearity and proportionality of FE 999049 in healthy
women (N = 6 per dose). AUC (a) and Cmax (b) following single
subcutaneous doses of 150–450 IU (Caucasian women) and
75–450 IU (Japanese women). The Caucasian group in the ‘Japanese’
study is indicated. Values are mean ± standard error of mean. AUC
area under the serum concentration-time curve, Cmax maximum serum
concentration
Table 4 Dose proportionality of AUC and Cmax after a single sub-
cutaneous administration of FE 999049
Parameter Caucasians (N = 18)
150–450 IU
Japanese (N = 23)
75–450 IU
Slope estimate 90 % CI Slope estimate 90 % CI
AUC 1.31 0.88–1.74 1.00 0.84–1.15
Cmax 1.16 0.84–1.49 0.91 0.77–1.05
The ratio and confidence intervals are estimated using an ANOVA on
the natural logarithm of the parameter and including treatment group
as fixed effect. Estimates are least square estimates from the model.
b was estimated using a linear regression model Ln(AUC/Cmax) =
a ? b 9 Ln(dose)
N number of subjects, AUC area under the serum concentration- time
curve, Cmax maximum serum concentration
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rFSH FE 999049 in the dose range 75–450 IU in Caucasian
and Japanese women. Moreover, there were no differences
in pharmacokinetic properties and dose proportionality
between Caucasian and Japanese women in this the first
investigation on the pharmacokinetics of rFSH in a Ja-
panese population. The results provide important infor-
mation for the selection of dose when a change in dose is
required during the treatment with rFSH in women un-
dergoing assisted reproductive technologies.
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